

## Materials and equipment

Fluorophore-labeled HLA class I tetramer(s)

Fluorophore-labeled antibodies against phenotypic markers (CD3, CD8, and other optional markers)

96-well U-bottom plate

FACS buffer: PBS with 1%BSA (or FCS) and 0.1% NaN<sub>3</sub>.

Centrifuge with a plate rotor

Flow cytometer

## Recommendations

Please note that the staining intensity can vary between tetramer specificities, hence the tetramer concentration should be titrated the first time a specific tetramer is used.

Note, it may be an advantage to stain for the same tetramer specificity with two different fluorochrome labels. It gives a more accurate definition of the tetramer positive population. It also allows for analysis of more than one T cell specificity in the same cell sample. Using various fluorochrome labeled tetramers each specificity can be defined by its unique two fluorochrome combination.

## HLA class I tetramer staining of human T cells

1. Prepare the cells of interest. For PBMC use  $1-2 \times 10^6$ , for cell lines use  $2-4 \times 10^5$
2. Transfer the cells to a 96-well U-bottom plate: Adjust the volume to 200 $\mu$ l with FACS buffer
3. Spin the plate at 700g for 3min. - flip out the supernatant in one smooth move.
4. Tetramer staining: Dilute the tetramer to 30 nM in FACS buffer and resuspend the pellet in 40  $\mu$ l of this dilution, and incubate in the dark at RT for 20 min.
5. Wash once in cold FACS buffer.
6. Spin the plate at 700g for 3min. - flip out the supernatant in one smooth move.
7. Co-stain with surface antibodies (CD8, CD3, other phenotype markers) prepare the antibody cocktail based on optimal staining concentration of each reagent.
8. Incubate in the dark at 4°C for 30 min.
9. Wash twice in cold FACS buffer.
10. Resuspend in FACS buffer and analyze in a Flow Cytometer.

## Assay background

This protocol is designed to evaluate the efficiency of peptide-HLA-I interaction and complex formation. The assay is based on detecting the  $\beta_2$ -microglobulin ( $\beta_2m$ ) light chain subunit of recombinant HLA class I (HLA-I) complexes, where the heavy chain has been biotin tagged. These tagged complexes are subsequently captured by streptavidin coated beads, labelled with PE-conjugated anti-human  $\beta_2m$ , and analyzed by flow cytometry. Since peptide-HLA-I complex formation is entirely peptide dependent, bead-associated signals will only be detected if the peptide in question supports the folding of the HLA-I allotype of interest; peptides that efficiently support folding will give strong signals whereas peptides that support folding sub-optimally, or not at all, will give moderate to non-detectable signals.

## Materials and equipment, you need to provide

Dilution buffer: PBS with 5% glycerol.

Streptavidin coated beads (6-8 $\mu$ m beads from Spherotech Cat# SVP-60-5)

FACS buffer: PBS with 1%BSA (or FCS) and 0.01% NaN<sub>3</sub>.

BBM.1-PE (anti-human  $\beta_2m$ ) (Santa Cruz Cat# sc-13565 PE)

U-bottom shape 96-well plate

Centrifuge with a plate rotor

Rocking table


Flow cytometer

Sealing Tape (Thermo Scientific Nunc™ cat# 236366)

## Protocol

- The folded HLA complexes are prepared according to protocol: “HLA-I tetramer production”. The folding setup should include a **positive control**: a peptide that is known to support folding of the HLA molecule of interest, and a **negative control**: without peptide.
- In the easyYmer folding set-up, the highest achievable concentration of the folded complex is 500nM.
- After completed folding incubation the complex formation can be evaluated.
- Prepare sufficient dilution buffer (PBS, 5% glycerol) for the whole assay.

- Dilute each of the folded complexes to give 75 $\mu$ L of a 40nM solution (e.g. for a 500nM complex: 6 $\mu$ L folded complex in 69 $\mu$ L dilution buffer).
- For all samples and **positive and negative controls**, transfer 50 $\mu$ L of this pre-dilution to the first tube. Make three subsequent serial 3-fold dilutions (50 $\mu$ L in 100 $\mu$ L dilution buffer), according to the figure below.



- Transfer 40 $\mu$ L of each these dilutions to the wells in a U-bottom shape 96-well plate, as suggested below. Also prepare a background well: transfer 40 $\mu$ L of dilution buffer.
- Prepare a sufficient volume of a 45-fold dilution of the streptavidin coated beads (6-8 $\mu$ m; SVP-60-5) in dilution

	1	2	3	4	5	6	7	8	9	10	11	12
A	Blank		P-1		S1-1		S3-1		S5-1		S7-1	
B			P-2		S1-2		S3-2		S5-2		S7-2	
C			P-3		S1-3		S3-3		S5-3		S7-3	
D												
E			N-1		S2-1		S4-1		S6-1		S8-1	
F			N-2		S2-2		S4-2		S6-2		S8-2	
G			N-3		S2-3		S4-3		S6-3		S8-3	
H												

Blank: No complex

P1-3: Dilutions of positive control; HLA with a known peptide binder

N1-3: Dilutions of negative control; HLA without peptide


S1- S8: Dilutions of the samples (complexes to evaluate)

buffer. Transfer 20 $\mu$ L of the beads solution to each well.

- Mix well and seal the plates with Sealing Tape to avoid well to well contamination.

10. Incubate the plate on a rocking table at 37°C for 1h.
11. Remove the Sealing Tape and wash by adding 160µl FACS buffer.
12. Spin the plate at 700g for 3min and flip out the supernatant.
13. Resuspend the beads in 200µl FACS buffer.
14. Spin the plate at 700g for 3min and flip out the supernatant.
15. Wash two more times by repeating step 13. and 14.
16. During the above washing steps, prepare a 200-fold dilution of the PE-labeled anti-human  $\beta_2m$  monoclonal antibody BBM.1 in FACS buffer
17. Resuspend the beads in 50µL antibody solution per well.
18. Incubate the plate for 30 min. at 4°C.
19. Wash by adding 150µl FACS buffer. Spin the plate at 700g for 3min and flip out the supernatant.
20. Resuspend the beads in 200µl FACS buffer. Spin the plate at 700g for 3min and flip out the supernatant.
21. Wash two more times by repeating step 19. and 20.
22. Resuspend the beads in 200µl FACS buffer, and analyze on a Flow cytometer.

## Example of the Flow cytometry-based assay:



### Flow cytometry-based detection of 4 different peptide-HLA-A\*02:01 complexes.

Complexes of A\*02:01 and 4 different peptides, and a negative control (No Peptide), were folded. CMV pp65<sub>495-503</sub> (NLVPMVATV) a known HLA-A\*02:01 restricted epitope was used as positive control. The three other peptides are based on their A\*02:01 binding stability categorized as good binder ( $T_{1/2}$  6.5h), intermediate binder ( $T_{1/2}$  3.5h), and low binder ( $T_{1/2}$  0.7h). Three dilutions of the folded complexes were analysed in the flow cytometry-based assay. The X-axis gives the complex concentration if complete folding is achieved.